Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 68

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

p53: From Fundamental Biology to Clinical Applications in Cancer

Capuozzo, Maurizio, Santorsola, Mariachiara, Bocchetti, Marco, Perri, Francesco, Cascella, Marco, Granata, Vincenza, Celotto, Venere, Gualillo, Oreste, Cossu, Alessia Maria, Nasti, Guglielmo, Caraglia, Michele, Ottaiano, Alessandro·2022·Biology
DOI 10.3390/biology11091325
Open this paper in CoChat — free account

Abstract

p53 tumour suppressor gene is our major barrier against neoplastic transformation. It is involved in many cellular functions, including cell cycle arrest, senescence, DNA repair, apoptosis, autophagy, cell metabolism, ferroptosis, immune system regulation, generation of reactive oxygen species, mitochondrial function, global regulation of gene expression, miRNAs, etc. Its crucial importance is denounced by the high percentage of amino acid sequence identity between very different species (Homo sapiens, Drosophila melanogaster, Rattus norvegicus, Danio rerio, Canis lupus familiaris, Gekko japonicus). Many of its activities allowed life on Earth (e.g., repair from radiation-induced DNA damage) and directly contribute to its tumour suppressor function. In this review, we provide paramount information on p53, from its discovery, which is an interesting paradigm of science evolution, to potential clinical applications in anti-cancer treatment. The description of the fundamental biology of p53 is enriched by specific information on the structure and function of the protein as well by tumour/host evolutionistic perspectives of its role.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/biology11091325

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Research works printed but not linked: 166

  1. Jay, 1979, Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse, Proc. Natl. Acad. Sci. USA, 76, 2420, 10.1073/pnas.76.5.2420 · DOI · Paper page
  2. Kastan, 1993, p53: Evolutionally conserved and constantly evolving, J. NIH Res., 5, 53
  3. Dippold, 1981, p53 transformation-related protein: Detection by monoclonal antibody in mouse and human cells, Proc. Natl. Acad. Sci. USA, 78, 1695, 10.1073/pnas.78.3.1695 · DOI · Paper page
  4. Linzer, 1979, The SV40 a gene product is required for the production of a 54,000 MW cellular tumor antigen, Virology, 98, 308, 10.1016/0042-6822(79)90554-3 · DOI · Paper page
  5. Rotter, 1983, p53, a transformation-related cellular-encoded protein, can be used as a biochemical marker for the detection of primary mouse tumour cells, Proc. Natl. Acad. Sci. USA, 80, 2613, 10.1073/pnas.80.9.2613 · DOI
  6. Sarnow, 1982, Adenovirus E1b-58kd tumour antigen and SV40 large tumour antigen are physically associated with the same 54 kd cellular protein in transformed cells, Cell, 28, 387, 10.1016/0092-8674(82)90356-7 · DOI · Paper page
  7. Wolf, 1985, Isolation of a full-length mouse cDNA clone coding for an immunologically distinct p53 molecule, Mol. Cell. Biol., 5, 127
  8. Eliyahu, 1984, Participation of p53 cellular tumour antigen in transformation of normal embryonic cells, Nature, 312, 646, 10.1038/312646a0 · DOI · Paper page
  9. Parada, 1984, Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation, Nature, 312, 649, 10.1038/312649a0 · DOI · Paper page
  10. Mowat, 1985, Rearrangements of the cellular p53 gene in erythroleukaemic cells transformed by Friend virus, Nature, 314, 633, 10.1038/314633a0 · DOI · Paper page
  11. Wolf, 1984, Inactivation of p53 gene expression by an insertion of Moloney murine leukemia virus-like DNA sequences, Mol. Cell. Biol., 4, 1402
  12. Chow, 1988, Inactivation of the p53 oncogene by internal deletion or retroviral integration in erythroleukemic cell lines induced by Friend leukemia virus, Oncogene, 3, 179
  13. Halevy, 1991, Frequent p53 mutations in chemically induced murine fibrosarcoma, Oncogene, 6, 1593
  14. Finlay, 1988, Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life, Mol. Cell. Biol., 8, 531
  15. Baker, 1989, Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas, Science, 244, 217, 10.1126/science.2649981 · DOI · Paper page
  16. Takahashi, 1989, p53: A Frequent Target for Genetic Abnormalities in Lung Cancer, Science, 246, 491, 10.1126/science.2554494 · DOI · Paper page
  17. Taneja, 2011, Transgenic and knockout mice models to reveal the functions of tumour suppressor genes, Clin. Med. Insights Oncol., 5, 235, 10.4137/CMO.S7516 · DOI
  18. Eliyahu, 1989, Wild-type p53 can inhibit oncogene-mediated focus formation, Proc. Natl. Acad. Sci. USA, 86, 8763, 10.1073/pnas.86.22.8763 · DOI · Paper page
  19. Harris, 1996, Structure and function of the p53 tumour suppressor gene: Clues for rational cancer therapeutic strategies, J. Natl. Cancer Inst., 88, 1442, 10.1093/jnci/88.20.1442 · DOI · Paper page
  20. Brady, 2011, Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumour suppression, Cell, 145, 571, 10.1016/j.cell.2011.03.035 · DOI · Paper page
  21. Lin, 1994, Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein, Genes Dev., 8, 1235, 10.1101/gad.8.10.1235 · DOI · Paper page
  22. Oliner, 1993, Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53, Nature, 362, 857, 10.1038/362857a0 · DOI · Paper page
  23. Kubbutat, 1997, Regulation of p53 stability by Mdm2, Nature, 387, 299, 10.1038/387299a0 · DOI · Paper page
  24. Walker, 1996, Identification of a novel p53 functional domain that is necessary for efficient growth suppression, Proc. Natl. Acad. Sci. USA, 93, 15335, 10.1073/pnas.93.26.15335 · DOI · Paper page
  25. Baptiste, 2022, The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumour cells, Oncogene, 21, 9, 10.1038/sj.onc.1205015 · DOI
  26. Venot, 1998, The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression, EMBO J., 17, 4668, 10.1093/emboj/17.16.4668 · DOI · Paper page
  27. Sakamuro, 1997, The polyproline region of p53 is required to activate apoptosis but not growth arrest, Oncogene, 15, 887, 10.1038/sj.onc.1201263 · DOI · Paper page
  28. Berger, 2001, A Role for the Polyproline Domain of p53 in Its Regulation by Mdm2, J. Biol. Chem., 276, 3785, 10.1074/jbc.M008879200 · DOI
  29. Toledo, 2007, Mouse mutants reveal that putative protein interaction sites in the p53 proline-rich domain are dispensable for tumor suppression, Mol. Cell. Biol., 27, 1425, 10.1128/MCB.00999-06 · DOI · Paper page
  30. Zhu, 1999, Differential regulation of cellular target genes by p53 devoid of the PXXP motifs with impaired apoptotic activity, Oncogene, 18, 2149, 10.1038/sj.onc.1202533 · DOI
  31. Baran, 2017, The proline rich domain of p53 is dispensable for MGMT-dependent DNA repair and cell survival following alkylation damage, Cell Death Differ., 24, 1925, 10.1038/cdd.2017.116 · DOI
  32. Rainwater, 1995, Role of cysteine residues in regulation of p53 function, Mol. Cell. Biol., 15, 3892, 10.1128/MCB.15.7.3892 · DOI · Paper page
  33. Halazonetis, 1993, Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants, EMBO J., 12, 5057, 10.1002/j.1460-2075.1993.tb06199.x · DOI · Paper page
  34. Chen, 2010, Crystal Structure of the p53 Core Domain Bound to a Full Consensus Site as a Self-Assembled Tetramer, Structure, 18, 246, 10.1016/j.str.2009.11.011 · DOI · Paper page
  35. Jeffrey, 1995, Crystal structure of the tetramerization domain of p53 tumour suppressor at 1.7 angstroms, Science, 267, 1498, 10.1126/science.7878469 · DOI · Paper page
  36. Stommel, 1999, A leucine-rich nuclear export signal in the p53 tetramerization domain: Regulation of subcellular localization and p53 activity by NES masking, EMBO J., 18, 1660, 10.1093/emboj/18.6.1660 · DOI · Paper page
  37. Weinberg, 2004, Cooperative Binding of Tetrameric p53 to DNA, J. Mol. Biol., 341, 1145, 10.1016/j.jmb.2004.06.071 · DOI · Paper page
  38. Dehner, 2005, Cooperative Binding of p53 to DNA: Regulation by Protein-Protein Interactions through a Double Salt Bridge, Angew. Chem. Int. Ed., 44, 5247, 10.1002/anie.200501887 · DOI
  39. Wagner, 1998, Fine mapping and regulation of the association of p53 with p34cdc2, Oncogene, 16, 105, 10.1038/sj.onc.1201510 · DOI
  40. Gabizon, R., Brandt, T., Sukenik, S., Lahav, N., Lebendiker, M., Shalev, D.E., Veprintsev, D., and Friedler, A. (2012). Specific Recognition of p53 Tetramers by Peptides Derived from p53 Interacting Proteins. PLoS ONE, 7. · DOI
  41. Maki, 1999, Oligomerization Is Required for p53 to be Efficiently Ubiquitinated by MDM2, J. Biol. Chem., 274, 16531, 10.1074/jbc.274.23.16531 · DOI
  42. Lee, 1995, p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches, Cell, 81, 1013, 10.1016/S0092-8674(05)80006-6 · DOI · Paper page
  43. Warnock, 2008, Influence of tetramerisation on site-specific post-translational modifications of p53: Comparison of human and murine p53 tumour suppressor protein, Cancer Biol. Ther., 7, 1481, 10.4161/cbt.7.9.6473 · DOI
  44. Liu, 2004, Facilitated search for specific genomic targets by p53 c-terminal basic DNA binding domain, Cancer Biol. Ther., 3, 1102, 10.4161/cbt.3.11.1189 · DOI
  45. Hupp, 1992, Regulation of the specific DNA binding function of p53, Cell, 71, 875, 10.1016/0092-8674(92)90562-Q · DOI · Paper page
  46. Laptenko, 2015, The p53 C Terminus Controls Site-Specific DNA Binding and Promotes Structural Changes within the Central DNA Binding Domain, Mol. Cell, 57, 1034, 10.1016/j.molcel.2015.02.015 · DOI · Paper page
  47. Shirangi, 2002, Nuclear degradation of p53 occurs during down-regulation of the p53 response after DNA damage, FASEB J., 16, 420, 10.1096/fj.01-0617fje · DOI
  48. Asher, 2003, p53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1, Proc. Natl. Acad. Sci. USA, 100, 15065, 10.1073/pnas.2436329100 · DOI
  49. Levine, 1997, p53, the Cellular Gatekeeper for Growth and Division, Cell, 88, 323, 10.1016/S0092-8674(00)81871-1 · DOI · Paper page
  50. Hunter, 1993, Braking the cycle, Cell, 75, 839, 10.1016/0092-8674(93)90528-X · DOI · Paper page
  51. Harper, 1993, The p21 Cdk interacting protein Cip1 is a potent inhibitor of G1 cyclin-depndent kinases, Cell, 75, 805, 10.1016/0092-8674(93)90499-G · DOI · Paper page
  52. Engeland, 2018, Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM, Cell Death Differ., 25, 114, 10.1038/cdd.2017.172 · DOI · Paper page
  53. Fischer, 2014, The transcription factor p53: Not a repressor, solely an activator, Cell Cycle, 13, 3037, 10.4161/15384101.2014.949083 · DOI · Paper page
  54. Zhan, 1999, Association with Cdc2 and inhibition of Cdc2/cyclin B1 kinase activity by the p53-regulated protein Gadd45, Oncogene, 18, 2892, 10.1038/sj.onc.1202667 · DOI · Paper page
  55. Tamura, 2012, GADD45 Proteins: Central Players in Tumorigenesis, Curr. Mol. Med., 12, 634, 10.2174/156652412800619978 · DOI · Paper page
  56. Pennington, 2018, The dynamic and stress-adaptive signaling hub of 14-3-3: Emerging mechanisms of regulation and context-dependent protein–protein interactions, Oncogene, 37, 5587, 10.1038/s41388-018-0348-3 · DOI · Paper page
  57. Park, 2000, Constitutive activation of cyclin B1-associated cdc2 kinase overrides p53-mediated G2-M arrest, Cancer Res., 60, 542
  58. Peng, 1997, Mitotic and G2 checkpoint control: Regulation of 14-3-3s protein binding by phosphorylation of cdc25C on serine 216, Science, 277, 1501, 10.1126/science.277.5331.1501 · DOI · Paper page
  59. Chiu, 2018, Mechanistic insights into avian reovirus p17-modulated suppression of cell cycle CDK–cyclin complexes and enhancement of p53 and cyclin H interaction, J. Biol. Chem., 293, 12542, 10.1074/jbc.RA118.002341 · DOI
  60. Stewart, 1995, Evidence for a second cell cycle block at G2/M by p53, Oncogene, 10, 109
  61. Taylor, 1999, Mechanisms of G2 Arrest in Response to Overexpression of p53, Mol. Biol. Cell, 10, 3607, 10.1091/mbc.10.11.3607 · DOI · Paper page
  62. Innocente, 1999, p53 regulates a G2 checkpoint through cyclin B1, Proc. Natl. Acad. Sci. USA, 96, 2147, 10.1073/pnas.96.5.2147 · DOI · Paper page
  63. Krause, 2000, The tumour suppressor protein p53 can repress transcription of cyclin B, Nucleic Acids Res., 28, 4410, 10.1093/nar/28.22.4410 · DOI · Paper page
  64. Strauss, 2018, Cyclin B1 is essential for mitosis in mouse embryos, and its nuclear export sets the time for mitosis, J. Cell Biol., 217, 179, 10.1083/jcb.201612147 · DOI
  65. 1997, Mammalian G1 and G2 phase checkpoints, Cancer Surv., 29, 151
  66. Todd, 2001, The effects of G-CSF mobilization on lymphocyte subsets, monocytes, NK cells, RBCs, platelets and CD34+/LIN-progenitors in normal allogeneic PBSC donors, Blood, 88, 2706
  67. Chen, 2006, Contribution of p16INK4a and p21CIP1 pathways to induction of premature senescence of human endothelial cells: Permissive role of p53, Am. J. Physiol. Heart Circ. Physiol., 290, H1575, 10.1152/ajpheart.00364.2005 · DOI · Paper page
  68. Giordano, 2012, Fenofibrate triggers apoptosis of glioblastoma cells in vitro: New insights for therapy, Cell Cycle, 11, 3154, 10.4161/cc.21719 · DOI
  69. Min, 2014, The effects of fucodian on senescence are controlled by the p16INK4a-pRb and p14Arf-p53 pathways in hepatocellular carcinoma and hepatic cell lines, Int. J. Oncol., 45, 47, 10.3892/ijo.2014.2426 · DOI
  70. Klaus, 1999, Radiation inducible DNA repair processes in eukaryotes, Biochimie, 81, 161, 10.1016/S0300-9084(99)80049-2 · DOI
  71. Smith, 1995, Involvement of the p53 tumour suppressor in repair of u.v.-type DNA damage, Oncogene, 10, 1053
  72. Sugasawa, 2010, Regulation of damage recognition in mammalian global genomic nucleotide excision repair, Mutat. Res. Mol. Mech. Mutagen., 685, 29, 10.1016/j.mrfmmm.2009.08.004 · DOI
  73. Schaeffer, 1994, The ERCC2/DNA repair protein is associated with the class II BTF2/TFIIH transcription factor, EMBO J., 13, 2388, 10.1002/j.1460-2075.1994.tb06522.x · DOI · Paper page
  74. Jayaraman, 1997, Identification of redox/repair protein Ref-1 as a potent activator of p53, Genes Dev., 11, 558, 10.1101/gad.11.5.558 · DOI · Paper page
  75. Gaiddon, 1999, Ref-1 regulates the transactivation and pro-apoptotic functions of p53 in vivo, EMBO J., 18, 5609, 10.1093/emboj/18.20.5609 · DOI · Paper page
  76. Hanson, 2005, Redox factor 1 (Ref-1) enhances specific DNA binding of p53 by promoting p53 tetramerization, Oncogene, 24, 1641, 10.1038/sj.onc.1208351 · DOI
  77. Chatterjee, 2006, The effect of p53-RNAi and p53 knockout on human 8-oxoguanine DNA glycosylase (hOgg1) activity, FASEB J., 20, 112, 10.1096/fj.04-3423fje · DOI
  78. Achanta, 2004, Role of p53 in Sensing Oxidative DNA Damage in Response to Reactive Oxygen Species-Generating Agents, Cancer Res., 64, 6233, 10.1158/0008-5472.CAN-04-0494 · DOI · Paper page
  79. Oka, 2015, MUTYH, an adenine DNA glycosylase, mediates p53 tumor suppression via PARP-dependent cell death, Oncogenesis, 4, e142, 10.1038/oncsis.2015.4 · DOI
  80. Kohno, 2016, Reduced MUTYH, MTH1, and OGG1 expression and TP53 mutation in diffuse-type adenocarcinoma of gastric cardia, Hum. Pathol., 52, 145, 10.1016/j.humpath.2016.01.006 · doi:10.1016/j.humpath.2016.01.006
  81. Vasovcak, P., Pavlikova, K., Sedláček, Z., Skapa, P., Kouda, M., Hoch, J., and Krepelová, A. (2011). Molecular Genetic Analysis of 103 Sporadic Colorectal Tumours in Czech Patients. PLoS ONE, 6. · DOI
  82. Modrich, 2006, Mechanisms in Eukaryotic Mismatch Repair, J. Biol. Chem., 281, 30305, 10.1074/jbc.R600022200 · DOI · Paper page
  83. Kafka, 2020, Mismatch Repair Pathway, Genome Stability and Cancer, Front. Mol. Biosci., 7, 122, 10.3389/fmolb.2020.00122 · DOI · Paper page
  84. Kunkel, 2005, DNA mismatch repair, Annu. Rev. Biochem., 74, 681, 10.1146/annurev.biochem.74.082803.133243 · DOI · Paper page
  85. Subramanian, 2002, Interactions between p53, hMSH2-hMSH6 and HMG I(Y) on Holliday junctions and bulged bases, Nucleic Acids Res., 30, 2427, 10.1093/nar/30.11.2427 · DOI
  86. Vaddavalli, 2022, The p53 network: Cellular and systemic DNA damage responses in cancer and aging, Trends Genet., 38, 598, 10.1016/j.tig.2022.02.010 · DOI · Paper page
  87. Zhang, 1995, Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression, Mol. Cell. Biol., 15, 3032, 10.1128/MCB.15.6.3032 · DOI · Paper page
  88. Wu, 1997, KILLER/DR5 is a DNA-damage inducible p53-regulated death receptor gene, Nat. Genet., 17, 141, 10.1038/ng1097-141 · DOI · Paper page
  89. Sionov, 1999, The cellular response to p53: The decision between life and death, Oncogene, 18, 6145, 10.1038/sj.onc.1203130 · DOI · Paper page
  90. Polyak, 1997, A model for p53-induced apoptosis, Nature, 389, 300, 10.1038/38525 · DOI · Paper page
  91. Joerger, 2010, The Tumor Suppressor p53: From Structures to Drug Discovery, Cold Spring Harb. Perspect. Biol., 2, a000919, 10.1101/cshperspect.a000919 · DOI · Paper page
  92. Pfister, 2017, Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53, Cold Spring Harb. Perspect. Med., 7, a026054, 10.1101/cshperspect.a026054 · DOI
  93. Lanfear, 2014, Population size and the rate of evolution, Trends Ecol. Evol., 29, 33, 10.1016/j.tree.2013.09.009 · DOI · Paper page
  94. Scally, 2016, The mutation rate in human evolution and demographic inference, Curr. Opin. Genet. Dev., 41, 36, 10.1016/j.gde.2016.07.008 · DOI
  95. Zhou, 2019, Mutant p53 in cancer therapy—the barrier or the path, J. Mol. Cell Biol., 11, 293, 10.1093/jmcb/mjy072 · DOI · Paper page
  96. McBride, 2014, Li-Fraumeni syndrome: Cancer risk assessment and clinical management, Nat. Rev. Clin. Oncol., 11, 260, 10.1038/nrclinonc.2014.41 · DOI · Paper page
  97. Yan, 2009, Identification of GRO1 as a Critical Determinant for Mutant p53 Gain of Function, J. Biol. Chem., 284, 12178, 10.1074/jbc.M900994200 · DOI
  98. Gurtner, 2010, Mutant p53-induced Up-regulation of Mitogen-activated Protein Kinase Kinase 3 Contributes to Gain of Function, J. Biol. Chem., 285, 14160, 10.1074/jbc.M109.094813 · DOI
  99. Girardini, 2011, A Pin1/mutant p53 axis promotes aggressiveness in breast cancer, Cancer Cell, 20, 79, 10.1016/j.ccr.2011.06.004 · DOI · Paper page
  100. Liao, 2017, Mutant p53 Gains Its Function via c-Myc Activation upon CDK4 Phosphorylation at Serine 249 and Consequent PIN1 Binding, Mol. Cell, 68, 1134, 10.1016/j.molcel.2017.11.006 · DOI
  101. Lisek, 2018, Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells, Oncotarget, 9, 20508, 10.18632/oncotarget.24974 · DOI
  102. Sui, 2013, Autophagy and chemotherapy resistance: A promising therapeutic target for cancer treatment, Cell Death Dis., 4, e838, 10.1038/cddis.2013.350 · DOI · Paper page
  103. Cordani, 2017, Molecular interplay between mutant p53 proteins and autophagy in cancer cells, Biochim. Biophys. Acta Rev. Cancer, 1867, 19, 10.1016/j.bbcan.2016.11.003 · DOI
  104. Kennedy, 2022, Mutant p53: It’s not all one and the same, Cell Death Differ., 29, 983, 10.1038/s41418-022-00989-y · DOI · Paper page
  105. Xia, 2022, Deciphering the acetylation code of p53 in transcription regulation and tumor suppression, Oncogene, 41, 3039, 10.1038/s41388-022-02331-9 · DOI · Paper page
  106. Bartel, 2009, MicroRNAs: Target Recognition and Regulatory Functions, Cell, 136, 215, 10.1016/j.cell.2009.01.002 · DOI · Paper page
  107. Qu, J., and Lin, Z. (2021). Autophagy Regulation by Crosstalk between miRNAs and Ubiquitination System. Int. J. Mol. Sci., 22. · DOI
  108. Condrat, C.E., Thompson, D.C., Barbu, M.G., Bugnar, O.L., Boboc, A., Cretoiu, D., Suciu, N., Cretoiu, S.M., and Voinea, S.C. (2020). miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis. Cells, 9. · DOI · Paper page
  109. Liu, 2017, MicroRNA Control of p53, J. Cell. Biochem., 118, 7, 10.1002/jcb.25609 · DOI
  110. Capaccia, C., Diverio, S., Zampini, D., and Guelfi, G. (2022). The Complex Interaction between p53 and miRNAs Joins New Awareness in Physiological Stress Responses. Cells, 11. · DOI
  111. Hu, 2010, Negative Regulation of Tumor Suppressor p53 by MicroRNA miR-504, Mol. Cell, 38, 689, 10.1016/j.molcel.2010.05.027 · DOI · Paper page
  112. Jones, 2012, MicroRNAs, wild-type and mutant p53: More questions than answers, RNA Biol., 9, 781, 10.4161/rna.20146 · DOI
  113. Okada, 2014, A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression, Genes Dev., 28, 438, 10.1101/gad.233585.113 · DOI · Paper page
  114. Park, 2009, miR-29 miRNAs activate p53 by targeting p85α and CDC42, Nat. Struct. Mol. Biol., 16, 23, 10.1038/nsmb.1533 · DOI · Paper page
  115. Li, 2014, Mutant p53 exerts oncogenic effects through microRNAs and their target gene networks, FEBS Lett., 588, 2610, 10.1016/j.febslet.2014.03.054 · DOI
  116. Garibaldi, 2016, Mutant p53 inhibits miRNA biogenesis by interfering with the microprocessor complex, Oncogene, 35, 3760, 10.1038/onc.2016.51 · DOI
  117. Muller, 2014, Mutant p53 Regulates Dicer through p63-dependent and -independent Mechanisms to Promote an Invasive Phenotype, J. Biol. Chem., 289, 122, 10.1074/jbc.M113.502138 · DOI
  118. Tragante, 2014, The ENCODE Project and Perspectives on Pathways, Genet. Epidemiol., 38, 275, 10.1002/gepi.21802 · DOI
  119. Nojima, 2022, Mechanisms of lncRNA biogenesis as revealed by nascent transcriptomics, Nat. Rev. Mol. Cell Biol., 23, 389, 10.1038/s41580-021-00447-6 · DOI · Paper page
  120. Alessio, E., Bonadio, R.S., Buson, L., Chemello, F., and Cagnin, S. (2020). A Single Cell but Many Different Transcripts: A Journey into the World of Long Non-Coding RNAs. Int. J. Mol. Sci., 21. · DOI
  121. Huarte, 2010, A Large Intergenic Noncoding RNA Induced by p53 Mediates Global Gene Repression in the p53 Response, Cell, 142, 409, 10.1016/j.cell.2010.06.040 · DOI · Paper page
  122. Pruszko, 2017, The mutant p53-ID4 complex controls VEGFA isoforms by recruiting lncRNA MALAT1, EMBO Rep., 18, 1331, 10.15252/embr.201643370 · DOI
  123. Wang, 2015, Exploring the Wnt Pathway-Associated LncRNAs and Genes Involved in Pancreatic Carcinogenesis Driven by TP53 Mutation, Pharm. Res., 32, 793, 10.1007/s11095-013-1269-z · doi:10.1007/s11095-013-1269-z
  124. Valenti, 2018, Long Non-coding MIR205HG Depletes Hsa-miR-590-3p Leading to Unrestrained Proliferation in Head and Neck Squamous Cell Carcinoma, Theranostics, 8, 1850, 10.7150/thno.22167 · DOI
  125. Huang, Q.-Y., Liu, G.-F., Qian, X.-L., Tang, L.-B., Huang, Q.-Y., and Xiong, L.-X. (2019). Long Non-Coding RNA: Dual Effects on Breast Cancer Metastasis and Clinical Applications. Cancers, 11. · DOI
  126. Sun, 2020, Orchestration of lincRNA-p21 and miR-155 in Modulating the Adaptive Dynamics of HIF-1α, Front. Genet., 11, 871, 10.3389/fgene.2020.00871 · DOI
  127. Yu, 2008, Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA, Nature, 451, 202, 10.1038/nature06468 · DOI · Paper page
  128. Qiu, 2015, Long non-coding RNA ANRIL predicts poor prognosis and promotes invasion/metastasis in serous ovarian cancer, Int. J. Oncol., 46, 2497, 10.3892/ijo.2015.2943 · DOI
  129. Donehower, 2019, Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas, Cell Rep., 28, 1370, 10.1016/j.celrep.2019.07.001 · DOI · Paper page
  130. Perri, 2016, p53 mutations and cancer: A tight linkage, Ann. Transl. Med., 4, 522, 10.21037/atm.2016.12.40 · DOI
  131. Jacquier, 2022, RIP140 inhibits glycolysis-dependent proliferation of breast cancer cells by regulating GLUT3 expression through transcriptional crosstalk between hypoxia induced factor and p53, Cell. Mol. Life Sci., 79, 270, 10.1007/s00018-022-04277-3 · DOI
  132. Han, 2019, p53 Promotes chemoresponsiveness by regulating hexokinase II gene transcription and metabolic reprogramming in epithelial ovarian cancer, Mol. Carcinog., 58, 2161, 10.1002/mc.23106 · DOI
  133. Yu, 2022, Emerging Roles of the Tumour Suppressor p53 in Metabolism, Front. Cell Dev. Biol., 18, 762742, 10.3389/fcell.2021.762742 · DOI
  134. Annesley, S.J., and Fisher, P.R. (2019). Mitochondria in Health and Disease. Cells, 8. · DOI · Paper page
  135. Johnson, 2012, Nuclear factor-κB, p53, and mitochondria: Regulation of cellular metabolism and the Warburg effect, Trends Biochem. Sci., 37, 317, 10.1016/j.tibs.2012.04.002 · DOI
  136. Blandino, 2020, Wild type- and mutant p53 proteins in mitochondrial dysfunction: Emerging insights in cancer disease, Semin. Cell Dev. Biol., 98, 105, 10.1016/j.semcdb.2019.05.011 · DOI
  137. Zhao, 2013, Mitochondrial dynamics regulates migration and invasion of breast cancer cells, Oncogene, 32, 4814, 10.1038/onc.2012.494 · DOI · Paper page
  138. Phan, 2022, Tumor suppressor p53 restrains cancer cell dissemination by modulating mitochondrial dynamics, Oncogenesis, 11, 26, 10.1038/s41389-022-00401-x · DOI
  139. Morita, 2017, mTOR Controls Mitochondrial Dynamics and Cell Survival via MTFP1, Mol. Cell, 67, 922, 10.1016/j.molcel.2017.08.013 · DOI · Paper page
  140. Yang, 2016, Mitochondria and Mitochondrial ROS in Cancer: Novel Targets for Anticancer Therapy, J. Cell. Physiol., 231, 2570, 10.1002/jcp.25349 · DOI · Paper page
  141. Nakamura, 2017, Discovery of Mieap-regulated mitochondrial quality control as a new function of tumor suppressor p53, Cancer Sci., 108, 809, 10.1111/cas.13208 · DOI
  142. Gupta, 2014, RECQL4 and p53 potentiate the activity of polymerase gamma and maintain the integrity of the human mitochondrial genome, Carcinogenesis, 35, 34, 10.1093/carcin/bgt315 · DOI
  143. Swann, 2007, Immune surveillance of tumors, J. Clin. Investig., 117, 1137, 10.1172/JCI31405 · DOI · Paper page
  144. Najafi, 2019, Macrophage polarity in cancer: A review, J. Cell. Biochem., 120, 2756, 10.1002/jcb.27646 · DOI · Paper page
  145. Walton, 2016, CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma, Cancer Res., 76, 6118, 10.1158/0008-5472.CAN-16-1272 · DOI · Paper page
  146. Wellenstein, 2019, Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis, Nature, 572, 538, 10.1038/s41586-019-1450-6 · DOI · Paper page
  147. Mehta, 2007, Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: Implications of p53 mutation or isoform expression on breast cancer cell invasion, Oncogene, 26, 3329, 10.1038/sj.onc.1210120 · DOI
  148. Mitkin, 2015, p53-dependent expression of CXCR5 chemokine receptor in MCF-7 breast cancer cells, Sci. Rep., 5, srep09330, 10.1038/srep09330 · DOI
  149. Nowak, 2015, MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2, Cancer Discov., 5, 636, 10.1158/2159-8290.CD-14-1113 · DOI
  150. Stark, 2018, Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion, Cancer Cell, 34, 298, 10.1016/j.ccell.2018.07.004 · DOI · Paper page
  151. Ruddell, 2008, p19/Arf and p53 suppress sentinel lymph node lymphangiogenesis and carcinoma metastasis, Oncogene, 27, 3145, 10.1038/sj.onc.1210973 · DOI
  152. Guo, 2013, Trp53 Inactivation in the Tumor Microenvironment Promotes Tumor Progression by Expanding the Immunosuppressive Lymphoid-like Stromal Network, Cancer Res., 73, 1668, 10.1158/0008-5472.CAN-12-3810 · DOI
  153. He, 2015, p53 in the Myeloid Lineage Modulates an Inflammatory Microenvironment Limiting Initiation and Invasion of Intestinal Tumors, Cell Rep., 13, 888, 10.1016/j.celrep.2015.09.045 · DOI
  154. Philip, 2004, Inflammation as a tumor promoter in cancer induction, Semin. Cancer Biol., 14, 433, 10.1016/j.semcancer.2004.06.006 · DOI · Paper page
  155. Wang, 2013, p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1, Nat. Commun., 4, 2359, 10.1038/ncomms3359 · DOI
  156. Heinemann, 2012, Tumor Suppressive MicroRNAs miR-34a/c Control Cancer Cell Expression of ULBP2, a Stress-Induced Ligand of the Natural Killer Cell Receptor NKG2D, Cancer Res., 72, 460, 10.1158/0008-5472.CAN-11-1977 · DOI · Paper page
  157. Yang, F., Wang, J.F., Wang, Y., Liu, B., and Molina, J.R. (2021). Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges. Cancers, 14. · DOI
  158. Siddiqui, S.S., Rahman, S., Rupasinghe, H.V., and Vazhappilly, C.G. (2020). Dietary Flavonoids in p53—Mediated Immune Dysfunctions Linking to Cancer Prevention. Biomedicines, 8. · DOI
  159. Menendez, 2013, Interactions between the tumor suppressor p53 and immune responses, Curr. Opin. Oncol., 25, 85, 10.1097/CCO.0b013e32835b6386 · DOI
  160. Lauwen, 2008, Self-Tolerance Does Not Restrict the CD4+ T-Helper Response against the p53 Tumor Antigen, Cancer Res., 68, 893, 10.1158/0008-5472.CAN-07-3166 · DOI
  161. Zwaveling, 2002, Antitumour efficacy of wild-type p53-specific CD4(+) T-helper cells, Cancer Res., 62, 6187
  162. Malekzadeh, 2019, Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers, J. Clin. Investig., 129, 1109, 10.1172/JCI123791 · DOI · Paper page
  163. Fishman, 2011, Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264–272)/HLA-A*0201 Complex, in Patients with Advanced Malignancies, Clin. Cancer Res., 17, 7765, 10.1158/1078-0432.CCR-11-1817 · DOI
  164. Bauer, 2021, Pharmacokinetic–pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies, Br. J. Cancer, 125, 687, 10.1038/s41416-021-01444-4 · DOI
  165. Dumble, 2021, Abstract LB006: PC14586: The first orally bioavailable small molecule reactivator of Y220C mutant p53 in clinical development, Cancer Res., 81, LB006, 10.1158/1538-7445.AM2021-LB006 · DOI · Paper page
  166. Yaghoubi, 2020, p28 Bacterial Peptide, as an Anticancer Agent, Front. Oncol., 10, 1303, 10.3389/fonc.2020.01303 · DOI

Cited by

See all 68

Metadata

Authors
Capuozzo, M., Santorsola, M., Bocchetti, M., Perri, F., Cascella, M., Granata, V., Celotto, V., Gualillo, O., Cossu, A. M., Nasti, G., Caraglia, M., & Ottaiano, A.
Affiliations
  • Coordinamento Farmaceutico, ASL-Naples-3, 80056 Ercolano, Italy
  • Istituto Nazionale Tumori di Napoli, IRCCS “G. Pascale”, Via M. Semmola, 80131 Naples, Italy
  • Department of Precision Medicine, University of Campania “L. Vanvitelli”, Via L. De Crecchio 7, 80138 Naples, Italy
  • SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago University Clinical Hospital, 15706 Santiago de Compostela, Spain
ORCID
Venue
Biology
Publisher
MDPI AG
Published
2022-09-06
Volume
11
Issue
9
Pages
1325
ISSN
2079-7737
DOI
10.3390/biology11091325
Cited by
68
References
26
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: p53: From Fundamental Biology to Clinical Applications in Cancer. https://app.cochat.ai/papers/10.3390/biology11091325
The paper
Capuozzo, M., Santorsola, M., Bocchetti, M., Perri, F., Cascella, M., Granata, V., Celotto, V., Gualillo, O., Cossu, A. M., Nasti, G., Caraglia, M., & Ottaiano, A. (2022). p53: From Fundamental Biology to Clinical Applications in Cancer. Biology. https://doi.org/10.3390/biology11091325

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.